Antibody-drug conjugates (ADCs) are potent therapeutic tools with promising efficacy in cancer treatment. Some ADCs, particularly those with microtubule-inhibiting payloads, have been linked to ocular side effects. For instance, Blenrep and Mirvetuximab soravtansine-gynx are associated with corneal microcyst-like epithelial changes, keratopathy, blurred vision, dry eye, and photophobia. Tivdak and Datroway, targeting tissue factor and TROP2, are also under investigation for cancer treatment. These ocular toxicities are believed to stem from nonspecific uptake of the cytotoxic payload by corneal epithelial cells, resulting in symptoms like blurred vision and photophobia. Patients on ADCs with known ocular side effects need close ophthalmic monitoring for effective risk management.
Read more from healio.com